Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 16/20 | 0.83 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.75 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | GALR3 | O60755 | 1/20 | 0.71 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.71 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.67 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.65 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.65 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.65 |
| ▸ | CDK1 | P06493 | 1/20 | 0.65 |
| ▸ | ROS1 | P08922 | 1/20 | 0.65 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.65 |
| ▸ | CDK2 | P24941 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodotubercidin SCHEMBL12618424 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL2786488 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL12505209 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL29383008 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL13021361 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL12652819 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL8328935 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL29375718 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL16978206 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL2043545 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 798 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630803-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-05-19 | — | — | US | claimed |
| US-20250340848-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4602148-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | Peking University (CN) | 2025-08-20 | — | — | EP | claimed |
| US-20250186593-A1 | TARGETED DELIVERY TO BETA CELLS | THE BROAD INSTITUTE, INC. | 2025-06-12 | — | — | US | claimed |
| US-12208140-B2 | Targeted delivery to beta cells | THE BROAD INSTITUTE, INC. (US) | 2025-01-28 | — | — | US | claimed |
| CN-118726563-A | Use of SNAP25 in diagnosis, treatment and prevention of ocular surface diseases | 天津医科大学眼科医院 | 2024-10-01 | — | — | CN | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| CN-118048296-B | Culture system, kit and method for reprogramming cells | 成都赛济元生物医药有限公司 | 2024-07-02 | — | — | CN | claimed |
| US-20240174983-A1 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-05-30 | — | — | US | claimed |
| CN-118048296-A | Culture system, kit and method for reprogramming cells | 成都赛济元生物医药有限公司 | 2024-05-17 | — | — | CN | claimed |
| EP-2021496-A2 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING HIV INFECTION | George Mason Intellectual Properties, Inc. (US) | 2009-02-11 | — | — | EP | claimed |
| WO-2008066626-A2 | METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR | THE ROCKEFELLER UNIVERSITY (US) | 2008-06-05 | — | — | WO | claimed |
| US-20080064026-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING HIV INFECTIONS | CENTER FOR APPLIED PROTEOMICS & MOLECULAR MEDICINE | 2008-03-13 | — | — | US | claimed |
| WO-2007130523-A2 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING HIV INFECTION | GEORGE MASON INTELLECTUAL PROPERTIES, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| EP-1578931-A4 | METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IGE SYNTHESIS UTILIZING AN ADENOSINE KINASE | RIGEL PHARMACEUTICALS INC (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2007022478-A2 | TRANSCRIPTION FACTORS IN NEURONAL DENDRITES-DENDRITIC PROTEIN SYNTHESIS AND CELL DEATH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CENTER FOR TECHNOLOGY TRANSFER (US) | 2007-02-22 | — | — | WO | claimed |
| EP-1578931-A2 | METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IGE SYNTHESIS UTILIZING AN ADENOSINE KINASE | Rigel Pharmaceuticals, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040096436-A1 | Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-05-20 | — | — | US | claimed |
| WO-2004012769-A1 | THERAPEUTIC INHIBITIONOF PROTEIN KINASES IN CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-02-12 | — | — | WO | claimed |
| WO-2004007680-A2 | METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IGE SYNTHESIS UTILIZING AN ADENOSINE KINASE | RIGEL PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174983-A1 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | IAPP, DYRK1A, GLP1R | ADK 191/4885SLC29A1 4366/4885DOT1L 2593/4885 |
| US-12630803-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | GLP1R, DYRK1A, DYRK1B | ADK 386/4885SLC29A1 3476/4885DOT1L 3150/4885 |
| US-20040096436-A1 | Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a | IMPDH1, IMPDH2, DCK | ADK 8/4885SLC29A1 353/4885DOT1L 2394/4885 |
| US-12208140-B2 | Targeted delivery to beta cells | IAPP, ZFR, ZC3H11A | ADK 2148/4885SLC29A1 1974/4885DOT1L 1635/4885 |
| US-20250186593-A1 | TARGETED DELIVERY TO BETA CELLS | IAPP, ZFR, ZC3H11A | ADK 2148/4885SLC29A1 1974/4885DOT1L 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.